Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Protein Networks02:26

Protein Networks

4.0K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K
Conjugated Proteins02:50

Conjugated Proteins

18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Cancer Vaccines01:30

Cancer Vaccines

389
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
389
Tumor Immunotherapy01:27

Tumor Immunotherapy

544
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Efficacy and Safety of B-Cell Maturation Antigen (BCMA) Antibody-Drug Conjugates (ADC) in Development against Cancer: A Systematic Review.

Oncology research·2026
Same author

A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor.

Biomarker research·2025
Same author

Ionic liquids as stabilisers of therapeutic protein formulations: a review of insulin and monoclonal antibodies.

Biophysical reviews·2025
Same author

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer.

Pharmaceutics·2023
Same author

Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers.

Journal of functional biomaterials·2023
Same author

Vaccine Hesitancy: Contemporary Issues and Historical Background.

Vaccines·2022

Related Experiment Video

Updated: Jul 14, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.

Candice Maria Mckertish1, Veysel Kayser1

  • 1Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Discovery Medicine
|October 9, 2023
PubMed
Summary

Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) offer targeted cancer therapies. This review examines conjugation strategies and innovations for optimizing ADC delivery while addressing challenges like stability and tumor penetration.

Keywords:
ADCantibody conjugated nanoparticlesantibody prodrug conjugatessite-specific conjugation

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

268
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.7K

Related Experiment Videos

Last Updated: Jul 14, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

268
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.7K

Area of Science:

  • Oncology
  • Biotechnology
  • Pharmaceutical Sciences

Background:

  • Cancer treatment increasingly relies on targeted therapies.
  • Monoclonal antibodies (mAbs) are a leading class of targeted therapeutics.
  • Antibody-drug conjugates (ADCs) leverage mAbs for targeted cancer drug delivery.

Purpose of the Study:

  • To review diverse mAb conjugation strategies for cancer therapy.
  • To explore innovative approaches for optimizing ADC drug delivery.
  • To identify challenges and limitations of current ADC technologies.

Main Methods:

  • Literature review of mAb conjugation strategies.
  • Analysis of pioneering ADC approaches for cancer treatment.
  • Examination of methods for optimizing drug delivery (site-directed conjugation, prodrugs, antibody-conjugated nanoparticles).

Main Results:

  • Various mAb conjugation strategies exist for ADCs.
  • Site-directed conjugation, prodrug conjugates, and antibody-conjugated nanoparticles show promise for optimized delivery.
  • Key challenges include ADC stability, drug resistance, payload retention, limited bioavailability, short half-life, and tumor penetration issues.

Conclusions:

  • Optimizing ADC drug delivery requires advanced conjugation strategies.
  • Addressing ADC limitations is crucial for improving cancer treatment efficacy.
  • Further innovation is needed to overcome challenges in the tumor microenvironment.